Company
Headquarters: Huzhou, China
Employees: 1,359
CN¥11.34 Billion
CNY as of Jan. 1, 2025
US$1.55 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. It also offers skin care and stem cells series. The company is headquartered in Huzhou, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥904.6 M |
| EBITDA | CN¥359.7 M |
| Gross Profit TTM | CN¥808.0 M |
| Profit Margin | 34.52% |
| Operating Margin | 43.05% |
| Quarterly Revenue Growth | 4.70% |
Zhejiang Wolwo Bio-Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300357 wb_incandescent